nuclear β-catenin positivity

Overview

Nuclear β-catenin positivity refers to the immunohistochemically or biochemically detected accumulation of β-catenin protein within the nucleus of a cell, a hallmark of aberrant canonical Wnt/β-catenin pathway activation. Under homeostatic conditions, β-catenin (encoded by the CTNNB1 gene) serves a dual role: it participates in cell–cell adhesion as a component of the E-cadherin–catenin complex at the plasma membrane, and it functions as a latent transcriptional co-activator held in check by a cytoplasmic destruction complex that includes GSK3β, APC, Axin, and casein kinase 1. Phosphorylation by GSK3β targets β-catenin for ubiquitin-proteasome-mediated degradation. When Wnt ligands engage their receptors, this destruction complex is inactivated, β-catenin accumulates in the cytoplasm, and the protein translocates to the nucleus, where it associates with TCF/LEF transcription factors—most notably TCF4—to drive expression of proliferative oncogenes such as MYC (c-MYC) and CCND1 (Cyclin D1).

Nuclear β-catenin positivity is therefore both a diagnostic marker and a mechanistic indicator of Wnt pathway dysregulation. It is routinely detected by immunohistochemistry in a wide spectrum of neoplastic and non-neoplastic conditions, ranging from desmoid fibromatosis and colorectal adenomas driven by CTNNB1 or APC mutations, to hepatocellular carcinoma, diffuse large B-cell lymphoma (DLBCL), glioblastoma, breast cancer, and lung adenocarcinoma. Beyond oncology, aberrant nuclear β-catenin activity has been documented in metabolic diseases such as type 2 diabetes, degenerative conditions including intervertebral disc degeneration and Age-related osteogenic failure, and ischemic neurological injury, underscoring the broad pathophysiological reach of this signaling node.

Focus of Latest Publications

Recent publications have continued to use nuclear β-catenin positivity as a readout of active Wnt/β-catenin signaling across several disease models, most often in cancer. In colorectal cancer, a study of valproic acid plus zebularine reported altered CTNNB1/β-catenin expression in colon cancer cells, with protein localization assessed in both cytoplasm and nucleus alongside morphological changes consistent with programmed cell death. The combination treatment reduced proliferation and was associated with downregulation of CTNNB1 in a dose-dependent manner. In diffuse large B-cell lymphoma, HDAC inhibition was linked to suppression of β-catenin signaling through BTG1, which inhibited formation of the β-catenin/TCF4 transcriptional complex and reduced downstream targets such as MYC and Cyclin D1.

Other studies connected nuclear β-catenin positivity to therapy response and resistance mechanisms. In glioblastoma, inhibition of miR-25-3p consistently suppressed β-catenin and re-induced FBXW7 expression in patient-derived cell lines, with some lines showing enhanced temozolomide sensitivity and reduced invasiveness. In triple-negative breast cancer, nitazoxanide was proposed as a ferroptosis inducer acting through dual disruption of iron homeostasis and the β-catenin/GPX4 axis, although the abstract did not provide detailed outcome data. In colorectal cancer immune evasion, β-catenin palmitoylation by ZDHHC5 stabilized the β-catenin/TCF4 complex, increasing SLC7A11 and PD-L1 expression to suppress immunogenic ferroptosis and inhibit CD8+ T-cell activity; blocking this palmitoyl-switch with β-cat-oxazole restored anti-tumor immunity and reduced tumor growth.

Beyond oncology, nuclear β-catenin positivity was also examined in metabolic, neurological, and skeletal contexts. In type 2 diabetes, CTNNB1 was identified as a differentially expressed gene, with reduced serum and pancreatic β-catenin levels in patients and diabetic mice; immunofluorescence showed spatial overlap between CTNNB1 and DLK1 in pancreatic islet cells, supporting a potential interaction. In ischemic stroke, resveratrol reversed the stroke-induced reduction in β-catenin and other Wnt proteins while preserving blood–brain barrier integrity. In osteoporosis, melatonin increased Wnt3a and β-catenin expression in osteoblast-related models and improved bone-related outcomes, while in a study of ginger-processed Magnolia bark, CTNNB1 emerged as a core network target among gastrointestinal disease-related nodes.

Key Publications

NEWJun Repurposing nitazoxanide as a novel ferroptosis inducer for triple-negative breast cancer via dual disruption of iron homeostasis and the β-catenin/GPX4 axis. (Redox report : communications in free radical research, 2026, PMID 42371677): "Nitazoxanide (NTZ), an FDA-approved antiparasitic with anticancer and redox activity, may be repurposed as a ferroptosis inducer, yet its effects and mechanisms in TNBC are unclear."
Jun Combinatorial drug repurposing of Valproic acid and Zebularine regulates Krüppel-like factor 4 and β-catenin expression in colon cancer cells. (PloS one, 2026, PMID 42224286): "Notably, CTNNB1 was downregulated than KLF4 in a dose dependent manner, potentially leading to antitumorigenic and anti-proliferative properties of the combinatorial drug."
Jun Hsa-miR-25-3p Inhibition Sensitizes Patient-Derived Glioblastoma Cells to Temozolomide via β-catenin Downregulation. (Cellular and molecular neurobiology, 2026, PMID 42218313): "...inhibition of miR-25-3p in GBM cell lines consistently suppressed β-catenin..."
Jun Druggable β-catenin palmitoyl-switch coordinates immune evasion via immunogenic ferroptosis resistance and PD-L1-mediated immunosuppression. (Cell reports. Medicine, 2026, PMID 42208545): "The palmitoylated state stabilizes the β-catenin/TCF4 complex, which simultaneously upregulates SLC7A11 to suppress immunogenic ferroptosis, critical for CD8+ T cell priming, and PD-L1 to inhibit cytotoxic CD8+ T cells, thereby impairing both the initiation and effector phases of anti-tumor immunity."
May Resveratrol modulates the sFRP4/Wnt signaling Pathway and preserves blood-brain barrier integrity in rats with ischemic stroke. (European journal of pharmacology, 2026, PMID 42114733): "Western blotting confirmed that resveratrol effectively reversed the stroke-induced upregulation of sFRP4, and also abrogated the stroke-induced downregulation of Wnt3a, Wnt4, Wnt5, Wnt11, and β-catenin levels."
May The molecular mechanism of melatonin in regulating osteoporosis based on the RANKL/OPG signaling axis. (Journal of molecular endocrinology, 2026, PMID 42023609): "Moreover, melatonin suppressed RANKL expression and promoted OPG, Wnt3a, and β-catenin expression."
May CTNNB1 Genetic Variation and Its Interaction With DLK1 in Type 2 Diabetes Mellitus. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 41961207): "β-catenin (CTNNB1) is a potential target for the treatment of T2DM."
Jun BTG1 Acts as a Critical Tumor Suppressor Link Between HDAC Inhibition and β-Catenin Signaling Suppression in Diffuse Large B-Cell Lymphoma. (Molecular carcinogenesis, 2026, PMID 41950351): "Mechanistically, BTG1 suppressed β-catenin signaling by inhibiting the formation of the β-catenin/TCF4 transcriptional complex, leading to reduced expression of downstream targets, including c-Myc and Cyclin D1."
May Elucidating the effects of ginger processing on Magnolia bark: A multi-platform strategy linking chemical composition to taste and bioactivity. (Journal of pharmaceutical and biomedical analysis, 2026, PMID 41520497): "Network pharmacology identified 51 overlapping targets across FD, PONV, and CG, with AKT1, TNF, CTNNB1, IL1B, and STAT3 as core nodes in the network."